1. Scrip
  2. >>Business

FTC Is Taking A Tougher Stance On Pharma; A Deputy Director Explains Why

 
• By Jessica Merrill

Deputy director of the Bureau of Competition Rahul Rao discussed the agency’s thinking on recent pharma deals that it viewed as anti-competitive.

• Source: Shutterstock

Federal Trade Commission Deputy director of the Bureau of Competition Rahul Rao said the regulatory group’s tougher stance on pharmaceutical deals stems from a general view that market incentives in the sector had grown misaligned with competitive practices.

Key Takeaways

  • FTC deputy director of the Bureau of Competition Rahul Rao discussed some of the agency’s recent actions on pharma deals.

“There wasn’t a seismic event that happened,” he said. “What we are seeing is greater consolidation. We’re seeing the effects...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Schrödinger Drops CDC7 Inhibitor SGR-2921 After Two Patient Deaths

 
• By Alaric DeArment

The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.

Finance Watch: OrbiMed’s New $1.86bn Fund Offers Financial Alternatives In Tough Market

 
• By Mandy Jackson

Public Company Edition: OrbiMed partners Carter Neild and Matthew Rizzo spoke with Scrip about the firm’s fifth royalty and credit fund. Also, Ligand sold $400m worth of notes, BridgeBio’s oncology spinout went public via SPAC merger and raised $261m and Assembly raised $175m.

Asia Deal Watch: Lupin Picks Sandoz To Market Lucentis Biosimilar In Parts Of EU And Asia

 
• By Joseph Haas, Sushmita Panda, Xu Hu, Vibha Ravi, and Manas Mishra

Also deals involving Xspray/Handa, Fosun/Expedition, Kaken/Astria, Orchid/Allecra, Sanofi/Visirna, KKR/Healthcare Royalty Partners, Viridian/Kissei, Sandoz/Evotec, Dx&Vx, Dr. Falk/Allianthera, Madrigal/CSPC and Lilly/LTZ.